The purchased assets include the BP+ suprasystolic central blood pressure device, the CardioReporter pulse pressure wave analysis software, and 34 blood pressure measurement and analysis patents, and 4 trademarks.
Pulsecor was purchased for about $2.9m at its last capital increase in May 2011 before the approvals of regulatory formalities.
The US Food and Drug Administration (FDA) has granted 510(k) for Pulsecor’s BP+ product. Besides, it has also received European CE mark and Australian Therapeutic Goods Administration (TGA).
The function of BP+ device is to measure the noninvasive central blood pressure at the heart by providing sensitive information about the health of the heart and vessels and is used to improve management of hypertension.
Uscom executive chairman Rob Phillips said combining noninvasive cardiac output with central blood pressure to provide accurate measurements otherwise only available with invasive cardiac catheters, puts the company a long way ahead of current clinical practice.
"This acquisition changes the game for Uscom and has significantly grown the opportunity of the company," Phillips added.
"The combined Uscom and Pulsecor patent portfolio also creates a product pipeline well into the future."
By combining the exact measurements of heart and vessel function using the Uscom products, USCOM 1A and the BP+, it is planned to create a new generation of noninvasive cardiovascular monitors.
These devices will be applicable in the ICU, the ED, paediatrics, military and retrieval applications, general ward, medical clinics, research applications and home care, and improve management in hypertension, sepsis, heart failure and fluid management.
K&L Gates (Australia) and BDO have served Uscom in the acquisition.
